(Q42211543)

English

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial

scientific article published on 5 June 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

phase III clinical trial

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

author name string

Gregory J Moran

1

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Edward Fang

2

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

G Ralph Corey

3

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Anita F Das

4

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Carisa De Anda

5

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Philippe Prokocimer

6

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

publication date

5 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Lancet Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

696-705

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical presentations of soft-tissue infections and surgical site infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Trends in US hospital admissions for skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemics of community-associated methicillin-resistant Staphylococcus aureus in the United States: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Meticillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment failure and costs in patients with methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections: a South Texas Ambulatory Research Network (STARNet) study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients: clinical characteristics, medical treatment, and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibiotics for skin infections: new study design and a step toward shorter course therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970737-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1473-3099(14)70737-6

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42211543&oldid=1936015405"